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Abstract
Background: Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) is being implemented
in most malaria endemic countries as a standard two-doses regimen as it reduces the risk of low birth weight
(LBW) and the prevalence of maternal anaemia. Nevertheless, where the risk of infection close to delivery is high
because of intense transmission, a third IPTp-SP dose may further reduce the negative effects of malaria on
pregnancy outcome.
Methods: Pregnant women in the 2nd or 3rd trimester were randomized to receive either 2 (SP2) or 3 doses (SP3)
of SP. Trained field workers paid home visits to the women for drug administration according to a predefined drug
delivery schedule. Women were encouraged to attend their scheduled ANC visits and to deliver at the health
facilities where the new-born was weighed. The prevalence of LBW (<2500 g), severe anaemia (Hb < 8 g/dL) and
premature birth was analysed using intention-to-treat (ITT) and per-protocol (PP) analysis.
Results: Data from 1274 singleton pregnancies were analysed (641 in the SP3 and 633 in the SP2 group). The
uptake of the intervention appeared to be low. Though the prevalence of LBW in both intervention groups was
similar (adjusted Incident Rate Ratio, AIRR = 0.92, 95%CI: 0.69-1.24) in the ITT analysis, the risk of severe anaemia
was significantly lower in the SP3 group compared to the SP2 group (AIRR = 0.38, 95%CI: 0.16 - 0.90). The PP
analysis showed a trend of reduced risk of LBW, severe anaemia and premature delivery in the SP3 group, albeit
the difference between two and three IPTp-SP did not reach statistical significance.
Conclusion: The risk of LBW and severe anaemia tended to be lower in the SP3 group, though this was not
statistically significant, probably due to the low uptake of the intervention which reduced the power of the study.
Further studies are needed for establishing whether a third SP dose has a real benefit in preventing the negative
effects of malaria in pregnancy in settings where transmission is markedly seasonal.
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Background
In Africa, in malaria endemic areas, about 30 million
pregnancies occur each year [1]. Though malaria infec-
tion during pregnancy is often asymptomatic where
transmission is moderate to high, it increases the risk of
maternal anaemia and low-birth-weight (LBW) (birth
weight < 2500 g) [2-5], the greatest risk factor for neo-
natal mortality and an important contributor to infant
mortality [6]. To prevent such adverse events, weekly
chemoprophylaxis with chloroquine (CQ) has been used
until recently. However, poor adherence to a weekly
schedule and, more importantly, the widespread resis-
tance to CQ [7-9], prompted its replacement with the
intermittent preventive treatment with sulphadoxine-
pyrimethamine (IPTp-SP) that can reduce the risk of
maternal anaemia, placental malaria and LBW [10-12].
SP has a good safety profile in pregnancy and the sin-
gle-dose regimen allows the direct observation of the
drug intake at the antenatal clinics (ANC). Therefore, in
areas of stable malaria transmission, provision to all
pregnant women of at least two doses of SP after quick-
ening has been recommended [13]. IPTp-SP is now
being implemented in most African endemic countries
at a standard two-dose regimen. In settings where HIV
prevalence is greater than 10%, a three-dose regimen is
recommended [13]. The latter may be beneficial also
where malaria transmission is markedly seasonal as
women receiving the second IPTp-SP dose more than
one month before delivery can still be re-infected [14].
Therefore, a third dose given as late in pregnancy as
acceptable, probably at 34-35 weeks gestation would
prevent placental re-infection and possibly reduce the
risk of LBW [12]. Though several studies investigated
the effect of monthly IPTp-SP [15,16], there is little evi-
dence that a third IPTp-SP dose offer any additional
benefit compared to the standard two-dose regimen
[13], particularly in a context of high SP efficacy [17,18].
Therefore, the two- and three-IPTp-SP doses regimens
were evaluated and compared in two peripheral health
centres in Burkina Faso and results are reported below.
Methods
Study settings
The study was conducted between March 2006 and July
2008 in two peripheral health centres (Koho and
Karaba) located in Houndé health district. Houndé is
situated at about 100 km from Bobo-Dioulasso, in west
Burkina Faso. Malaria is holo-endemic with marked sea-
sonal (June - December) transmission [19]. The district
hospital and the 28 peripheral health facilities located in
its catchment area cover a population of approximately
247,500 people [20]. In 2007, it was estimated that
about 12,500 pregnant women were at risk of malaria.
Malaria represented 38% of all consultations and 52% of
hospitalizations in the health district. Attendance rates
to the 2nd ANC visit was estimated at 69.6%. Only
25.2% pregnant women attended the ANC before the
second trimester of pregnancy. The prevalence of LBW
among deliveries in health facilities was estimated at
16.0%, one of the highest figures in Burkina Faso [20].
Before its implementation as IPTp, SP resistance was
low in Burkina Faso, with the PCR-adjusted treatment
failure at day 28 among children 6 months-15 years of
age estimated at 8.2% [21].
Study design
This study was part of a larger one investigating the
impact of a fortified food supplement (FFS) versus mul-
tiple micronutrients supplement (MMS) on pregnancy
outcome [22]. Pregnant women were randomized using
a factorial design in permuted blocks of four to receive
either: (1) two-dose SP + FFS, (2) two-dose SP + MMS,
(3) three-dose SP + FSS or (4) three-dose SP + MMS.
Therefore, for malaria participants were assigned to
receive either the two-dose SP (SP2 group) as recom-
mended by the National Malaria Control Program
(NMCP) in Burkina Faso, or the three-dose SP (SP3
group) regimen. Randomization numbers generated by a
computer programme were printed and sealed in indivi-
dual opaque envelopes that were opened only when the
study physician identified an eligible subject. Drug
administrations were scheduled by a field pharmacist
according to the gestational age at randomization and
given at home by the field workers. Nutritional supple-
mentation consisted of a daily administration of MMS
or FFS as described elsewhere [22]. The sample size was
estimated on the proportion of LBW as the primary out-
come. Assuming the prevalence of LBW in the control
group (SP2) at 15% and a loss to follow up around 10%,
542 participants per arm should be able to show a 40%
reduction (from 15% to 9%) in LBW at 80% power and
5% significance.
Study participants
The study participants were recruited through a com-
munity-based network of 30 field workers, as described
by Huybregts et al [22]. Briefly, during a census, all
women of childbearing age in the study area were iden-
tified and registered. Monthly visits by trained field
workers were carried out over the whole study area to
screen for pregnant cases. When pregnancy was sus-
pected, participants were referred to one of the two
health facilities for a formal pregnancy test. Written
informed consent was obtained from those agreeing to
participate to the study after explaining the study pur-
pose and procedures. Women with known hypersensi-
tivity to SP or not planning to stay in the study area for
the following two years were excluded. The study
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protocol was approved by the Ethical Committees of the
Centre Muraz, Bobo-Dioulasso, Burkina Faso, and the
Institute of Tropical Medicine, Antwerp, Belgium. The
study was registered at http://ClinicalTrial.gov registry
(identifier: NCT00909974).
Clinical procedures
Women were enrolled at the first ANC visit. Demo-
graphic data and medical and pregnancy history were
recorded. Clinical examination was performed and vital
signs, weight, height and arm circumference were
recorded. These measures were repeated at each ANC
visit. Gestational age was assessed by an obstetrician by
performing a trans-abdominal ultrasound foetal biome-
try. The field workers visited the women at home for the
drug administration according to the predefined drug
delivery schedule. All women received the first IPTp-SP
dose at the beginning of the second trimester of preg-
nancy, after quickening, and the second one at the begin-
ning of the third trimester as recommended by the
NMCP. In addition, women in the SP3 group received a
third IPTp-SP dose one month after the second dose if
this one occurred before 34 weeks of gestation. If not, the
administration of the third dose was cancelled. Women
identified during the first trimester of pregnancy did not
receive any anti-malarial treatment before the second tri-
mester of pregnancy unless they had clinical malaria
defined by a positive slide at any parasite density together
with fever. If so, they were referred to the health facilities
to receive an appropriate care. Women were paid home
visits daily by the field workers who collected information
about any complaint after their previous visit and
recorded body temperature. In case of fever (body tem-
perature ≥37.5°C) or history of fever since the last visit, a
blood sample for parasitaemia (thick and thin blood film)
and later genotyping (on filter paper) was collected.
Women with malaria infection were treated with a full
course of quinine (24 mg/kg/day for 7 days). Pregnant
women were encouraged to attend their scheduled ANC
visits and to deliver at the health facilities where the new-
born was weighed and measured twice by two different
members of the health staff.
Laboratory procedures
Duplicate thick and thin blood smears were collected at
different time points, i.e. at the first ANC visit, before
SP administration, whenever a malaria infection was
suspected and at delivery. Slides were stained with
Giemsa 10% (pH 7.2) and parasites were counted against
200 WBC. Ten percent of the slides were randomly
selected and sent to the Centre Muraz for quality con-
trol. Maternal haemoglobin (Hb) was measured by
Hemocue (HemoCue Ltd, UK) at the first and the third
ANC visits.
Main variables and definitions
Primary outcome was LBW prevalence. Secondary out-
comes were the occurrence of anaemia, miscarriage, pre-
maturity, stillbirth and neonatal mortality. LBW was
defined as birth weight < 2500 g. Anaemia and severe
anaemia were defined as Hb < 11 g/dL and Hb < 8 g/
dL, respectively. Miscarriage was defined as delivery
before 28 weeks of gestation; prematurity as ≤37 weeks
of gestation, according to the gestational age at enrol-
ment as given by the ultrasound biometry; stillbirth as
delivery of a dead baby after 28 weeks of gestation; neo-
natal death as death within the first 28 days of life. Ado-
lescents were defined as women ≤ 19 years old. Malaria
infection was defined as detection by microscopy of
Plasmodium falciparum asexual stages, any density.
Explanatory variables and possible confounders included
the study arm, the number of SP doses received (1, 2 or
3), parity (3 groups: primigravidae, gravidae 2-3, gravi-
dae ≥4), body mass index at enrolment, malaria infec-
tion, malaria transmission season at delivery (low
transmission season from January to May and high
transmission season from June to December) and the
nutritional supplement group women belonged to.
Statistical analysis
Data were double entered in a Microsoft Access® data-
base. Validation and analysis were performed using
Stata/IC® version 10.0 software. Only singleton pregnan-
cies were included in the analysis. Intention-to-treat
(ITT) and a per-protocol (PP) analysis were performed.
Since a substantial proportion of women in the SP3
group did not received the third dose of SP, an addi-
tional individual efficacy (IE) analysis was carried out.
The ITT analysis included all randomized patients for
whom the outcome variables were available and the
effect of the intervention was determined by comparing
the SP2 group to the SP3 group, regardless of the actual
number of IPTp-SP doses received by the women. The
PP analysis included women randomized in the SP3
group who actually received three doses and women
randomized in the SP2 group who received two doses of
SP and for whom the outcomes data were available. The
IE analysis divided women in groups according to the
number of IPTp-SP doses actually received (one, two or
three), regardless of the randomization group they
belonged to.
Comparison of mean values of continuous variables
was done by analysis of variance, while for categorical
variables a Poisson regression model with robust stan-
dard error estimates was used to evaluate the relation-
ship between explanatory variables and outcomes.
Parity, maternal age, corrected weight status at inclusion
(underweight: body mass index <18.5 kg/m2; or normal
weight) malaria infection and malaria transmission
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season at delivery were included in the model as possi-
ble confounders. A p-value ≤ 0.05 was considered as sta-
tistically significant.
Results
A total of 1,296 pregnant women were randomized: 656
in the SP3 and 640 in the SP2 group. However, in the
SP3 group only 149 (23%) women received the third SP
dose, while 261 (41%) women received the second SP
dose in the SP2 group. Twenty-four women moved out
of the study area and no delivery information could be
obtained. For 167 women, birth weight was not available
because they delivered at home and could not be
referred to the health facility or the health workers
failed to weigh the new-born when delivery occurred at
a health facility. Twenty two pregnancies were non-sin-
gleton. Overall, the analysis of birth weight was carried
out in 1,034 new-borns (Figure 1). The baseline charac-
teristics were comparable between the two groups
(Table 1). About 1/4 of the women (326/1296) were
adolescents.
The prevalence of LBW was 13.44% (139/1034) and
was strongly related with parity. According to ITT ana-
lysis, no difference in LBW was found between the two
study groups, and this did not change after stratifying
by parity (Table 2). Women of gravidity 2-3 (adjusted
Incident Rate Ratio, AIRR = 0.49, 95%CI: 0.32 - 0.75),
gravidity ≥ 4 (AIRR = 0.26, 95%CI: 0.15-0.47) and BMI
≥18 kg/m2 (AIRR = 0.65, 95%CI: 0.44-0.96) had signifi-
cantly lower risk of LBW while delivery in the high
transmission season was associated with an increased
risk of LBW (AIRR = 1.39, 95%CI: 1.02-1.90).
The prevalence of anaemia and severe anaemia in the
third trimester of pregnancy was 44.66% (569/1274) and
1.98% (25/1274), respectively. Severe anaemia occurred
significantly less in the SP3 than in the SP2 group
(AIRR 0.38, 95%CI: 0.16 - 0.90). No difference in anae-
mia between SP3 and SP2 was found. About 18% (227/
Figure 1 Study flow diagram
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1242) women delivered prematurely; there were 41
spontaneous abortions (3.3%), 27 stillbirths (2.17%), and
31 neonatal deaths (2.43%). For these outcomes, no dif-
ference between the study groups was found (Table 2).
According to the PP analysis, the proportion of LBW
(2-dose SP: 11.9%, 3-dose SP: 9.6%), severe anaemia
(2-dose SP: 2.3%, 3-dose SP: 1.7%) and premature deliv-
ery (2-dose SP: 11.3, 3-dose SP: 9.5%) tended to
decrease with the number of SP doses received, albeit it
did not reach statistical significance (Table 3), and this
occurred also for most outcomes after stratifying by
gravidity.
For the IE analysis, three groups of women were
defined: those having received one dose (515), two doses
(472), and three doses (149). Women were excluded
when the number of SP doses received was unknown
(138/1296, 10.65%).
In primigravidae, the risk of LBW was significantly
different between those having received one (41.4%,
36/87), two (25%, 21/84) and three IPTp-SP (13.6%,
3/22) doses (p = 0.012), though the difference between
two and three IPTp-SP doses did not reach statistical
significance (p = 0.47). Similarly, in this subgroup, the
mean birth weight was significantly different between
primigravidae having received one (2570 g), two (2703
g) or three IPTp-SP (2821 g) (p = 0.04) but not between
those having received two and three doses (p = 0.87).
The risk of severe anaemia in the third trimester (one
3.6%, 4/110, two 2.9%, 3/111, three 0.0%, 0/24) and of
premature delivery (one 33.0%, 36/106; two 20.0%, 20/
100; three 12.0%, 3/24) was also significantly different
according to the number of IPTp-SP doses taken but
not between those having received two and three doses
(data not shown). In all other gravidae, no difference
according to the number of IPTp-SP could be found.
Discussion
This study had the objective of establishing the benefits
of adding a third SP dose to the standard two-dose
IPTp-SP regimen on pregnancy outcome. However, a
significant proportion of women randomized to the SP3
group did not receive the third SP dose and this reduced
substantially the power of the study. Unfortunately, such
problem was identified only at the time of the statistical
analysis, when no corrective action could be taken. The
trial comparing SP2 against SP3 was carried out within
a larger study looking at nutritional supplementation
during pregnancy, in which women had to be visited
daily by field workers. This was thought to be a major
advantage as women should have been carefully moni-
tored and the timing of SP administration planned well
in advance. Conversely, such careful follow up did not
translate in high coverage of the intervention, rather in
an extremely low uptake of the third SP dose. The rea-
sons for such results are unclear but definitely cannot
be attributed to the low performance of the health sys-
tem as the intervention was delivered by field workers
supervised by the local research team. It should be
noted that randomization was not stratified by gesta-
tional age and this may have resulted in the inclusion of
late pregnancies in which the third dose could not be
administered before delivery. Nevertheless, most
Table 1 Characteristic of study participants at inclusion
by randomization group
Characteristics SP3 group
(n = 649)
SP2 group
(n = 625)
Study location
Karaba village (n, %) 152 (23.42) 173(27.68)
Koho village (n, %) 497 (76.58) 452(72.32)
Education
none (n, %) 576 (90.85) 528(86.70)
primary (n, %) 45 (7.10) 66 (10.84)
secondary and
higher (n, %)
13 (2.05) 15 (2.46)
Ethnicity
bwaba (n, %) 160 (24.65) 165 (26.40)
mossi (n, %) 423 (65.18) 400 (64.00)
peuhl (n, %) 37 (5.70) 41 (6.56)
other (n, %) 29 (4.47) 19 (3.04)
Occupation
farmer/housewife (n, %) 625(96.30) 609 (97.44)
student (n, %) 2 (0.31) 6 (0.96)
other (n, %) 4 (0.62) 5 (0.80)
missing (n, %) 18 (2.77) 5 (0.80)
Parity
primigravidae (n, %) 130 (20.03) 135 (21.60)
secundigravidae (n, %) 143 (22.03) 119 (19.04)
multigravidae (n, %) 376 (57.94) 371 (59.36)
Gestation at enrolment
first trimester (n, %) 263 (40.52) 235 (37.60)
second trimester (n, %) 345 (53.16) 343 (54.88)
third trimester (n, %) 41 (6.32) 47 (7.52)
Age
mean (years) (95% CI) 24.26 (23.80-24.73) 24.66 (24.15-25.17)
Weight
mean (kg) (95% CI] 55.40 (54.86-55.94) 55.36 (54.82-55.92)
Height
mean (cm) (95% CI] 162.77 (162.32-
163.25)
162.50 (162.04-
162.96)
BMI at enrolment
mean (95% CI] 20.88 (20.72-21.04) 20.95 (20.77-21.13)
Prevalence of peripheral
infection
114 (17.57%) 123 (19.68%)
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pregnant women were identified relatively early, mainly
during the second trimester, and should have been able
to receive the third SP dose. The more likely explana-
tion is that this was an ancillary study, carried out
within a larger nutrition project, and that the local
research team probably either misunderstood the drug
administration schedule, failing to provide SP at the
required time, or was ‘too busy’ in managing the large
amount of data produced by the daily visits. The low
coverage is clearly a major weakness of this study
though it should be considered that most of the SP
third doses were administered to women randomized to
the SP3 group. Therefore, a major selection bias is
unlikely; rather the study has a lower power than
expected and is unable to provide robust conclusions
about the benefit of the third SP dose. This is obvious
when considering the results obtained by the ITT and
PP analysis. In the former no difference in the occur-
rence of LBW and anaemia was found, an expected
result when considering the substantial number of preg-
nant women in SP3 group having received just 1 or 2
SP doses, diluting any possible difference. In the PP ana-
lysis, the risk for LBW, severe anaemia and premature
delivery tended to be lower in the SP3 as compared to
the SP2 group though, due to the small sample size and
hence the low power, such difference does not reach
Table 2 Intention to treat analysis of outcomes for women randomized in the trial using Poisson regression analysis
with robust error estimation (crude and adjusted Incident rate ratio).
Prevalence (Proportion) of
women with characteristics
Crude IRR
(95% CI)
Adjusted IRR*
(95% CI)
Characteristics SP2 group SP3 group
Overall
LBW 14.1 (73/519) 12.8 (66/515) 0.91 (0.67 - 1.24) 0.92 (0.69 - 1.24)
Anaemia 44.8 (280/625) 44.5 (289/649) 0.99 (0.87 - 1.12) 0.99 (0.88 - 1.12)
Severe anaemia 2.8 (18/625) 1.1 (7/649) 0.37 (0.16 - 0.89)a 0.38 (0.16 - 0.90)b
Premature delivery (%) 18.2 (111/610) 18.3 (116/632) 1.00 (0.79 - 1.27) 0.97 (0.77 - 1.24)
Spontaneous abortion (%) 2.8 (17/610) 3.8 (24/632) 1.36 (0.74 - 2.51) 1.36 (0.74 - 2.53)
Stillbirth 1.6 (10/610) 2.7 (17/635) 1.63 (0.75 - 3.54) 1.64 (0.74 - 3.61)
Neonatal death 2.1 (13/625) 2.8 (18/649) 1.33 (0.83 - 3.20) 1.32 (0.81 - 3.23)
Gravidae 1
LBW 30.6 (34/111) 33.3(33/99) 1.08 (0.73 - 1.61) 1.05 (0.71 - 1.56)
Anaemia 47.4(64/135) 50.0 (65/130) 1.05 (0.82 - 1.35) 1.05 (0.82 - 1.34)
Severe anaemia 5.2 (7/135) 1.5 (2/130) 0.29 (0.06 - 1.40) 0.29 (0.05 - 1.46)
Premature delivery (%) 29.4 (38/129) 25.8 (33/128) 0.87 (0.58 - 1.30) 0.81 (0.55 - 1.18)
Spontaneous abortion (%) 4.7 (6/129) 8.6 (11/128) 1.84 (0.70 - 4.85) 1.51 (0.59 - 3.86)
Stillbirth 3.1 (4/129) 3.9 (5/128) 1.26 (0.34 - 4.59) 1.23 (0.30 - 4.89)
Neonatal death 5.2 (7/135) 5.4 (7/130) 1.04 (0.37 - 2.88) 0.95 (0.32 - 2.82)
Gravidae 2-3
LBW 13.4 (24/179) 11.3 (21/186) 0.84 (0.48 - 1.45) 0.86 (0.50 - 1.46)
Anaemia 45.1 (97/215) 39.0 (92/236) 0.86 (0.69 - 1.07) 0.88 (0.71 - 1.09)
Severe anaemia 3.3 (7/215) 1.7 (4/236) 0.52 (0.15 - 1.75) 0.54 (0.16 - 1.84)
Premature delivery (%) 17.6 (37/210) 20.9 (48/230) 1.18 (0.80 - 1.74) 1.10 (0.75 -1.60)
Spontaneous abortion (%) 1.4 (3/209) 2.2 (5/230) 1.50 (0.36 - 6.27) 1.47 (0.38 - 5.62)
Stillbirth 0.5 (1/209) 2.6 (6/232) 5.40 (0.65 - 44.63) 5.85 (0.66 - 51.31)
Neonatal death 0.5 (1/215) 2.1 (5/236) 4.49 (1.04 - 34.32) 8.8 (1.08 - 51.49)
Gravidae ≥4
LBW 6.6 (15/229) 5.2 (12/230) 0.79 (0.38 - 1.66) 0.78 (0.37 - 1.64)
Anaemia 43.3 (119/275) 46.6 (132/283) 1.07 (0.89 - 1.29) 1.06 (0.87 - 1.28)
Severe anaemia 1.5 (4/275) 0.4 (1/283) 0.24 (0.03 - 2.16) 0.24 (0.03 - 2.16)
Premature delivery (%) 13.3 (36/271) 12.8 (35/274) 0.96 (0.37 - 1.27) 0.95 (0.60 - 1.47)
Spontaneous abortion (%) 2.9 (8/272) 2.9 (8/274) 0.99 (0.37 - 2.60) 0.99 (0.37 - 2.60)
Stillbirth 1.8 (5/272) 2.2 (6/275) 1.18 ( 0.36- 3.84) 1.11 (0.34 - 3.63)
Neonatal death 1.8 (5/275) 2.1 (6/283) 1.16 (0.35 - 3.78) 1.11 (0.34 - 3.62)
*Adjusted for age category, BMI, malaria infection, malaria season at delivery, supplementation and parity category (the later for the overall analysis only),
ap= 0.026, bp = 0.030
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statistical significance, a result illustrated by the wide
AIRRs’ 95% confidence intervals. Therefore, the study
results are inconclusive in regards of the potential bene-
fits of a third IPTp-SP dose on reducing the risk of
LBW.
Nevertheless, the decreasing trend of LBW, severe
anaemia and premature delivery risk observed in the PP
analysis may be an indication of the possible additional
effect of the 3rd dose of SP. The significantly lower risk of
severe anaemia in the SP3 group could be considered as
an indication of the beneficial effect of the third SP dose
though this was not confirmed by the PP analysis, most
likely because of the small number of women included in
this analysis. A reduction in the risk of severe anaemia is
plausible as, though of complex aetiology, known causes
including worm infections, nutrient deficiencies and
chronic inflammation [23], maternal anaemia has been
also associated to placental malaria [23] so that a third
SP dose, by reducing such a risk, could have also
improved the haematological status. The nutritional sup-
plements received by the women included in the study
should have further reduced the risk of maternal anaemia
by preventing folic acid and iron deficiency, the latter fre-
quently observed in sub-Saharan African women [24].
Indeed the daily dose included at least 400 μg of folic
acid and 30 mg of iron as part of the FFS or MMS.
In the IE analysis, the effect of two or three doses of
IPTp-SP was more evident in primigravidae. In areas of
Table 3 Per Protocol analysis of pregnancy outcomes for women randomized in the trial using Poisson regression
analysis with robust error estimation (crude and adjusted incident rate ratios)
Prevalence (Proportion) of women
with characteristics
Crude IRR
(95% CI)
Adjusted IRR*
(95% CI)
Characteristics 2-dose SP 3-dose SP
Overall
LBW 11.9 (28/235) 9.6 (13/136) 0.80 (0.42 - 1.49) 0.84 (0.45 - 1.54)
Anaemia 46.1 (119/258) 50.7 (75/148) 1.09 (0.89 - 1.35) 1.12 (0.91 - 1.38)
Severe anaemia 2.3 (6/258) 1.4 (2/148) 0.58 (0.12 - 2.84) 0.63 (0.12 - 3.46)
Premature delivery (%) 11.3 (29/257) 9.5 (14/148) 0.83 (0.46 - 1.53) 0.77 (0.43 - 1.35)
Spontaneous abortion (%) 1.2 (3/257) 2.0 (3/148) 1.73 (0.35 - 8.51) 1.56 (0.34 - 7.10)
Stillbirth 1.2 (3/257) 2.7 (4/148) 2.31 (0.5 - 10.22) 2.32 (0.47 - 11.36)
Neonatal death 1.3 (2/136) 1.5 (2/136) 1.15 (0.19 - 6.82) 1.29 (0.21 - 7.99)
Gravidae 1
LBW 19.2 (9/47) 13.6 (3/22) 0.71 (0.21 - 2.39) 0.78 (0.22 - 2.72)
Anaemia 63.5 (33/52) 58.3 (14/24) 0.92 (0.62 - 1.36) 1.00 (0.68 - 1.49)
Severe anaemia 3.9 (2/52) 0 - -
Premature delivery (%) 17.3 (9/52) 12.5 (3/24) 0.72 (0.21 - 2.45) 0.56 (0.15 - 2.09)
Spontaneous abortion (%) 3.9 (2/52) 4.2 (1/24) 1.08 (0.10 - 11.52) 0.31 (0.08 - 1.25)
Stillbirth 1.9 (1/52) 0 - -
Neonatal death 4.3 (2/47) 0 - -
Gravidae 2-3
LBW 15.4 (12/78) 11.5 (6/52) 0.75 (0.29 -1.87) 0.81 (0.32 - 2.01)
Anaemia 41.7 (35/84) 43.9 (25/57) 1.05 (0.71 - 1.55) 1.10 (0.73 - 1.66)
Severe anaemia 2.4 (2/84) 1.8 (1/57) 0.89 (0.06 - 8.00) 0.92 (0.10 - 8.77)
Premature delivery (%) 15.5 (13/84) 12.3 (7/57) 0.79 (0.34 - 1.87) 0.77 (0.35 - 1.68)
Spontaneous abortion (%) 0 1.8 (1/57) - -
Stillbirth 0 5.3 (3/57) - -
Neonatal death 0 0.8 (1/130) - -
Gravidae ≥4
LBW 6.4 (7/110) 6.5 (4/62) 1.01 (0.31 - 3.34) 1.09 (0.32 - 3.68)
Anaemia 41.8 (51/122) 53.7 (36/67) 1.28 (0.95 - 1.75) 1.26 (0.92 - 1.71)
Severe anaemia 1.6 (2/122) 1.5 (1/67) 0.91 (0.08 - 9.91) -
Premature delivery (%) 5.8 (7/121) 5.9 (4/67) 0.72 (0.21 - 2.45) -
Spontaneous abortion (%) 0.8 (1/121) 1.5 (1/67) - -
Stillbirth 1.6 (2/121) 1.5 (1/67) 0.90 (0.08 - 9.83) 0.77 (0.04 - 15.87)
Neonatal death 0.9 (1/110) 1.6 (1/62) 1.77 (0.11 - 2.80) -
*Adjusted for age category, BMI, malaria infection, malaria season at delivery, supplementation and parity category (the later in the overall analysis only)
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intense transmission, their higher vulnerability to
malaria infection and its negative consequences are well
known [5]. In these settings, any intervention against
malaria should have a more profound effect in this
group than in secundi- and multigravidae. Indeed, in a
study on the effectiveness of IPTp-SP carried out in
Burkina Faso, in a similar setting, the impact of two
IPTp-SP doses as compared to one or none was more
marked in primigravidae than in secundigravidae [17].
In addition, according to a Cochrane review, anti-malar-
ial drugs reduce significantly severe antenatal anaemia
and LBW, and increase birth weight in women in their
first and second pregnancy [25].
In conclusion, no difference on LBW risk was found
by adding a third dose of SP to the standard 2-dose
regimen, though a trend of reduced risk was observed.
Such finding does not exclude a beneficial effect of a
third IPTp-SP dose, rather additional and more carefully
carried out studies are needed to establish the potential
benefits and the feasibility of this strategy in areas of
intense malaria transmission.
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